Compare Monster Beverage Corp (MNST) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs TG Therapeutics Inc — how do they compare? Monster Beverage Corp trades at $43.66 (market cap $85.51B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Monster Beverage Corp is far larger — about 10.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and TG Therapeutics Inc for 16 Days on average.
| MNST | TGTX | |
|---|---|---|
Market Cap | $85.51B | $8.16B |
Volume | 8,569,709 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $59.06 |
52-Week Low | $33.16 | $26.94 |
Typical Hold Time | 72 Days | 16 Days |
Enterprise Value | $83.81B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.64, up 1.77% today. The stock exhibits a bullish technical trend, with recent earnings consistently beating estimates. Revenue grew to $8.29 billion in 2025, with a strong net income margin of 23.08%. A recent 1:2 stock split occurred on August 11, 2026. Analyst consensus is a 'Buy' with a $98.22 price target, indicating significant upside potential from current levels.
The outlook is positive, driven by robust international expansion and a debt-free balance sheet. Key risks include intense competition and regulatory challenges, as seen in India. Earnings growth remains the primary catalyst, but the stock's high valuation multiples require sustained performance to justify further gains.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
